LobbyingNationwide Children's Hospital lobbying by quarter
Nationwide Children's Hospital's latest lobbying report covers Q2 2026, at $80K. The four quarters Q4 2025–Q3 2026 total $350K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Medicare/Medicaid.
Nationwide Children's Hospital
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $350K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $40K | 1 |
| Q1 2023 | $100K | 1 |
| Q2 2023 | $50K | 1 |
| Q3 2023 | $50K | 1 |
| Q4 2023 | $40K | 1 |
| Q1 2024 | $110K | 1 |
| Q2 2024 | $40K | 1 |
| Q3 2024 | $45K | 1 |
| Q4 2024 | $40K | 1 |
| Q1 2025 | $170K | 1 |
| Q2 2025 | $50K | 1 |
| Q3 2025 | $57K | 1 |
| Q4 2025 | $50K | 1 |
| Q1 2026 | $220K | 1 |
| Q2 2026 | $80K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$571K · 15 reports
- Medicare and Medicaid$571K · 15 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- Centers For Medicare and Medicaid Services (CMS)15 reports
- Health & Human Services, Dept of (HHS)15 reports
- HOUSE OF REPRESENTATIVES15 reports
- SENATE15 reports
- Health Resources & Services Administration (HRSA)14 reports
- Food & Drug Administration (FDA)11 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseNationwide Children's Hospital | $1.1M | 15 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/15for Q2 | In-house | $80K |
| 04/20for Q1 | In-house | $220K |
| 01/21for Q4 2025 | In-house | $50K |
| 25/10/20for Q3 2025 | In-house | $57K |
| 25/07/21for Q2 2025 | In-house | $50K |
| 25/04/28for Q1 2025 | In-house | $170K |
| 25/01/20for Q4 2024 | In-house | $40K |
| 24/10/17for Q3 2024 | In-house | $45K |
| 24/07/18for Q2 2024 | In-house | $40K |
| 24/04/22for Q1 2024 | In-house | $110K |
| 24/01/22for Q4 2023 | In-house | $40K |
| 23/10/20for Q3 2023 | In-house | $50K |
| 23/07/21for Q1 2023 | In-house | $100K |
| 23/07/18for Q2 2023 | In-house | $50K |
| 23/04/24for Q1 2023 | In-house | $90K |
| 23/01/20for Q4 2022 | In-house | $40K |